Dr. Reddy's Laboratories Limited
NYSE:RDYDrug Manufacturers - Specialty & Generic
-$0.15 today
- Market cap
- $12.48B
- Beta
- 0.26
- P/E (TTM)
- 24.7
- EPS (TTM)
- $51.40
- Dividend yield
- 0.63%
Volume 1.79M
Average 2.39M
RDY Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Dr. Reddy's Laboratories LimitedNYSE: RDY
Depreciation & Amortization · Q2 FY2027 · quarter ended Sep 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q2 FY2027 depreciation & amortization of ₹5.26B rose 4.2% year over year, behind the +12.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 2.0% from the prior quarter. Over 3 fiscal years it compounded at +19.7% a year.
Context
- Depreciation & amortization amounted to 6.1% of revenue in FY2026, up 0.9 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +4.2% toward the trailing-twelve-month pace of +12.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
INR · from the income statement
- Latest · FY2026
- 21.68B INR
- Year-over-year change
- +27.1%
- 4-year CAGR
- +16.4%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 21.68B | +27.1% |
| FY2025 | 2025-03-31 | 17.06B | +14.9% |
| FY2024 | 2024-03-31 | 14.84B | +17.5% |
| FY2023 | 2023-03-31 | 12.64B | +6.9% |
| FY2022 | 2022-03-31 | 11.82B | — |
Depreciation & Amortization vs competitors
How RDY compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +12.7% is the 2nd highest of 7, against a peer median of -0.8%.
- Depreciation & amortization amounts to 6.5% of revenue for RDY, versus a peer median of 8.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | ₹21.51B INR | +12.7% | +19.7% | 6.5% | |
| LTM Jun 2026 | $2.8B USD | +1.6% | -2.6% | 19.0% | |
| LTM Jun 2026 | $1.17B USD | -5.6% | -4.7% | 10.8% | |
| LTM Jun 2026 | $989M USD | -3.3% | -8.5% | 5.7% | |
| LTM Jun 2025 | £379M GBP | — | +7.1% | 2.3% | |
| LTM Jun 2026 | $194.29M USD | -20.8% | -2.4% | 6.2% | |
| LTM Mar 2026 | $89.45M USD | +17.8% | +15.3% | 9.7% | |
| LTM Mar 2026 | $62.85M USD | +7.5% | +30.7% | 8.7% | |
| Peer median (excluding RDY) | — | -0.8% | -2.4% | 8.7% | |
Competitors are the stored peer set for RDY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 214.39B | 245.88B | 279.16B | 325.54B | 353.47B |
| Cost of Revenue | 100.55B | 106.54B | 115.56B | 135.11B | 166.95B |
| Gross Profit | 113.84B | 139.34B | 163.61B | 190.43B | 186.52B |
| Gross Margin | 53.1% | 56.7% | 58.6% | 58.5% | 52.8% |
| Research & Development | 17.48B | 19.38B | 22.87B | 27.38B | 25.31B |
| Selling, General & Admin | 62.08B | 68.03B | 77.2B | 93.87B | 112.34B |
| Operating Expenses | 84.36B | 82.2B | 95.88B | 118.59B | 137.65B |
| Depreciation & Amortization | 11.82B | 12.64B | 14.84B | 17.06B | 21.68B |
| EBITDA | 45.08B | 74.43B | 88.42B | 96.67B | 83.29B |
| EBITDA Margin | 21.0% | 30.3% | 31.7% | 29.7% | 23.6% |
| Operating Income | 29.48B | 57.14B | 67.73B | 71.84B | 48.87B |
| Operating Margin | 13.7% | 23.2% | 24.3% | 22.1% | 13.8% |
| Interest Income | 965M | 1.18B | 2.28B | 2.68B | 8.28B |
| Interest Expense | 958M | 1.43B | 1.71B | 2.83B | 3.93B |
| Other Income / Expenses | 2.82B | 3.22B | 4.14B | 4.94B | 8.81B |
| Income Before Tax | 32.3B | 60.37B | 71.87B | 76.78B | 57.68B |
| Pre-Tax Margin | 15.1% | 24.6% | 25.7% | 23.6% | 16.3% |
| Income Tax Expense | 8.73B | 15.3B | 16.19B | 19.54B | 13B |
| Net Income | 23.57B | 45.07B | 55.68B | 56.54B | 45.09B |
| Net Margin | 11.0% | 18.3% | 19.9% | 17.4% | 12.8% |
| EPS (Basic) | 28.42 | 54.29 | 66.80 | 67.85 | 53.92 |
| EPS (Diluted) | 28.34 | 54.17 | 66.80 | 67.77 | 53.92 |
| Weighted Avg Shares | 829.41M | 830.17M | 833.54M | 833.31M | 832.41M |
| Weighted Avg Shares (Diluted) | 831.69M | 831.91M | 833.54M | 834.3M | 833.26M |
Dr. Reddy's Laboratories Limited
NYSE:RDY
Intrinsic Alpha fair value
Locked
Current Price
$14.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.